Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

This is a specimen collection study where patients with high-risk stage I germ cell tumor, clinical stage II germ cell tumor, and clinical stage III germ cell tumor will be evaluated for ctDNA.

Inclusion criteria

• ≥ 18 years old at the time of informed consent
• Ability to provide written informed consent and HIPAA authorization
• Subjects must have histologically or serologically confirmed seminomatous or non seminomatous germ cell tumor. Non-seminoma includes embryonal carcinoma, choriocarcinoma, yolk sac tumor, or teratoma.

Note: Cohort I is for high-risk clinical stage I disease (high risk will be defined as per enrolling investigator discretion). Cohort II is for clinical stage II. Cohort III is for clinical stage III or IS.

• Archival tissue for germ-cell tumor diagnosis available

Exclusion criteria

• Concurrent disease or condition that would make the subject inappropriate for study participation
• Any serious medical disorder that would interfere with the subject's safety
• Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent per treating physician coverage.
• Patient is being tested for minimal residual disease with other experimental platforms